跳至主要内容
临床试验/NL-OMON30258
NL-OMON30258尚未招募不适用

A Phase I randomized, open-label, single dose, 3-period crossover trial in healthy subjects to evaluate the relative oral bioavailability of the 25 mg and 100 mg tablets of TMC125. - Trial to evaluate the relative bioavailability of TMC125.

TIBOTEC Pharmaceuticals Ltd., Little Island, Co. Cork; Ireland in Nederland vertegenwoordigd door Janssen-Cilag BV0 个研究点目标入组 36 人开始时间: 待定最近更新:
适应症

试验速览

阶段
不适用
状态
尚未招募
发起方
入组人数
36

研究概览

简要总结

暂无简介。

研究设计

研究类型
Interventional

入排标准

年龄范围
18 至 99(—)

入选标准

  • Participants may not have smoked for the last 3 months preceding the start of the trial. Participants have to be healthy on base of physical examination, medical history, ECG, laboratory tests and blood pressure and pulse rate.

排除标准

  • Participants may not have (had) relevant skin diseases or use medicines. The participants may not have participated in more than 1 study with TMC125, TMC120 and/or TMC278 (previously R278474) or having developed rash while participating in a trial with any of these compounds. Females may not be fertile anymore.

研究者

发起方
TIBOTEC Pharmaceuticals Ltd., Little Island, Co. Cork; Ireland in Nederland vertegenwoordigd door Janssen-Cilag BV

相似试验